RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sprint Bioscience Stock

Sprint Bioscience ROE 2024

Sprint Bioscience ROE

-0.02

Ticker

SPRINT.ST

ISIN

SE0006343745

WKN

A14NY2

In 2024, Sprint Bioscience's return on equity (ROE) was -0.02, a -99.26% increase from the -2.13 ROE in the previous year.

Sprint Bioscience Aktienanalyse

What does Sprint Bioscience do?

The Swedish company Sprint Bioscience AB is an innovative developer of drugs targeted for use in cancer. The company was founded in Stockholm in 2009 and has since worked with a strong focus on molecular research. Sprint Bioscience is a biotechnology company with the goal of developing drugs for various types of cancer. The company's focus is on so-called "trickster molecules" that can prevent tumor cells from taking up nutrients, ultimately leading to their death. The innovative business model of Sprint Bioscience is that they focus on the discovery and development of molecules, which they then sell to larger pharmaceutical companies that further develop and bring them to market. Sprint Bioscience has a wide range of molecular tools that allow for the identification, development, and optimization of cancer therapy drugs. The company aims to accelerate the discovery of new drugs in the field of oncology. Sprint Bioscience is divided into two business areas: discovery, which specializes in the identification and optimization of drugs for use in cancer, and development, which focuses on the preclinical development of drugs that are later further developed by larger pharmaceutical companies. The most well-known product of Sprint Bioscience is the molecule "SB-11285", a novel cancer therapeutic specifically developed for ovarian cancer. The molecule is intended to help destroy cancer cells by disrupting their cellular metabolism and depriving them of their energy source. Sprint Bioscience has also formed partnerships with other companies to exchange technologies and expertise. For example, there is a collaboration with Bayer to develop new oncology drugs. Overall, Sprint Bioscience has undergone significant development in recent years. The company has built strong expertise in the field of molecular research and effectively implemented its business model. Sprint Bioscience presents itself as a promising player in the biotechnology industry and has the potential to achieve further significant progress in the coming years. Sprint Bioscience ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Sprint Bioscience's Return on Equity (ROE)

Sprint Bioscience's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Sprint Bioscience's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Sprint Bioscience's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Sprint Bioscience’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Sprint Bioscience stock

What is the ROE (Return on Equity) of Sprint Bioscience this year?

The ROE of Sprint Bioscience this year is -0.02 undefined.

How has the Return on Equity (ROE) of Sprint Bioscience developed compared to the previous year?

The ROE of Sprint Bioscience has increased by -99.26% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Sprint Bioscience?

A high ROE indicates that Sprint Bioscience generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Sprint Bioscience?

A low ROE can indicate that Sprint Bioscience is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Sprint Bioscience affect the company?

A change in ROE (Return on Equity) of Sprint Bioscience can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Sprint Bioscience?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Sprint Bioscience?

Some factors that can influence Sprint Bioscience's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Sprint Bioscience pay?

Over the past 12 months, Sprint Bioscience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sprint Bioscience is expected to pay a dividend of 0 SEK.

What is the dividend yield of Sprint Bioscience?

The current dividend yield of Sprint Bioscience is .

When does Sprint Bioscience pay dividends?

Sprint Bioscience pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sprint Bioscience?

Sprint Bioscience paid dividends every year for the past 0 years.

What is the dividend of Sprint Bioscience?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sprint Bioscience located?

Sprint Bioscience is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sprint Bioscience kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sprint Bioscience from 7/22/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 7/22/2024.

When did Sprint Bioscience pay the last dividend?

The last dividend was paid out on 7/22/2024.

What was the dividend of Sprint Bioscience in the year 2023?

In the year 2023, Sprint Bioscience distributed 0 SEK as dividends.

In which currency does Sprint Bioscience pay out the dividend?

The dividends of Sprint Bioscience are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sprint Bioscience

Our stock analysis for Sprint Bioscience Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sprint Bioscience Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.